Prelude Therapeutics Incorporated filed a current report on Form 8-K on September 10, 2026, disclosing that the U.S. Food and Drug Administration cleared the company to proceed with a Phase 1 study for PRT13722, a KAT6A degrader being developed for HR+ breast cancer.

Key Highlights

  • FDA Clearance: The U.S. Food and Drug Administration cleared Prelude Therapeutics to proceed with a Phase 1 study under its Investigational New Drug Application for PRT13722.
  • Drug Candidate: PRT13722 is described in the filing as a KAT6A degrader.
  • Target Indication: PRT13722 is being developed for the treatment of patients with HR+ breast cancer.
  • Disclosure Method: The announcement was made via a press release dated September 10, 2026, filed as Exhibit 99.1.
  • Investor Materials: The company also prepared investor presentation materials, filed as Exhibit 99.2, intended for use in investor presentations.
  • Signing Officer: The report was signed by Bryant Lim, Chief Financial Officer and Chief Legal Officer.

Prelude Therapeutics Discloses IND Clearance for KAT6A Degrader PRT13722

According to the filing, Prelude Therapeutics Incorporated (NASDAQ:PRLD) disclosed on September 10, 2026, that the U.S. Food and Drug Administration cleared the company to proceed with a Phase 1 study under its Investigational New Drug Application for PRT13722. The company described PRT13722 as a KAT6A degrader being developed for the treatment of patients with HR+ breast cancer. The disclosure was made under Item 7.01 Regulation FD and was accompanied by a press release issued the same day, attached as Exhibit 99.1.

The company also disclosed that it had prepared investor presentation materials intended for use in investor presentations, attached as Exhibit 99.2. The filing noted that the information furnished in the current report and its exhibits "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934" and is not incorporated by reference into any other filing of the company under the Securities Act of 1933 or the Exchange Act.

Prelude Therapeutics is incorporated in Delaware and lists its principal executive offices at 175 Innovation Boulevard, Wilmington, Delaware 19805. Its common stock, with a par value of $0.0001 per share, is registered on the Nasdaq Global Select Market under the trading symbol PRLD. The report was signed by Bryant Lim in his capacity as Chief Financial Officer and Chief Legal Officer.

What Was Disclosed

Prelude Therapeutics reported that the FDA cleared a Phase 1 study for PRT13722, a KAT6A degrader targeting HR+ breast cancer, under an Investigational New Drug Application. The company also furnished investor presentation materials alongside the announcement.